RT Journal Article
T1 Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study.
A1 Mohammadi, Mahmoud
A1 IJzerman, Nikki S
A1 Hohenberger, Peter
A1 Rutkowski, Piotr
A1 Jones, Robin L
A1 Martin-Broto, Javier
A1 Gronchi, Alessandro
A1 Schöffski, Patrick
A1 Vassos, Nikolaos
A1 Farag, Sheima
A1 Baia, Marco
A1 Oosten, Astrid W
A1 Steeghs, Neeltje
A1 Desar, Ingrid M E
A1 Reyners, An K L
A1 van Sandick, J W
A1 Bastiaannet, Esther
A1 Gelderblom, Hans
A1 Schrage, Yvonne
K1 Gastrointestinal stromal tumours
K1 Oesophagus
K1 Surgery
K1 Survival
K1 Treatment outcome
AB Oesophageal gastrointestinal stromal tumours (GISTs) account for ≤1% of all GISTs. Consequently, evidence to guide clinical decision-making is limited. Clinicopathological features and outcomes in patients with primary oesophageal GIST from seven European countries were collected retrospectively. Eighty-three patients were identified, and median follow up was 55.0 months. At diagnosis, 59.0% had localized disease, 25.3% locally advanced and 13.3% synchronous metastasis. A biopsy (Fine Needle aspiration n = 29, histological biopsy n = 31) was performed in 60 (72.3%) patients. The mitotic count was low (5/5hpf) mitotic count were associated with worse disease free survival. Based on the current study, enucleation can be recommended for oesophageal GIST smaller than 4 cm, while oesophagectomy should be preserved for larger tumours. Patients with larger tumours (>4 cm) and/or high mitotic count should be treated with adjuvant therapy.
YR 2021
FD 2021-03-31
LK https://hdl.handle.net/10668/27243
UL https://hdl.handle.net/10668/27243
LA en
DS RISalud
RD Apr 4, 2025